Bausch Health Companies (BHC) Raised to Hold at ValuEngine

ValuEngine upgraded shares of Bausch Health Companies (NYSE:BHC) from a sell rating to a hold rating in a report released on Tuesday.

Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald reiterated a buy rating and set a $32.00 price objective on shares of Bausch Health Companies in a research note on Tuesday, August 7th. Mizuho reiterated a buy rating and set a $31.00 price objective on shares of Bausch Health Companies in a research note on Tuesday, August 7th. Deutsche Bank set a $30.00 price objective on shares of Bausch Health Companies and gave the stock a buy rating in a research note on Wednesday, September 12th. Zacks Investment Research upgraded shares of Bausch Health Companies from a hold rating to a buy rating and set a $31.00 price objective on the stock in a research note on Wednesday, October 3rd. Finally, Royal Bank of Canada increased their price objective on shares of Bausch Health Companies from $25.00 to $26.00 and gave the stock a hold rating in a research note on Wednesday, August 8th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $27.55.

BHC traded down $0.09 on Tuesday, hitting $27.20. 3,898,414 shares of the company’s stock were exchanged, compared to its average volume of 4,904,969. The firm has a market cap of $9.48 billion, a price-to-earnings ratio of 7.10, a price-to-earnings-growth ratio of 0.37 and a beta of -0.28. Bausch Health Companies has a twelve month low of $13.86 and a twelve month high of $28.45. The company has a quick ratio of 0.89, a current ratio of 1.14 and a debt-to-equity ratio of 7.55.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Tuesday, November 6th. The company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.31. The firm had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.09 billion. Bausch Health Companies had a negative net margin of 40.41% and a positive return on equity of 32.19%. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. Research analysts anticipate that Bausch Health Companies will post 3.7 earnings per share for the current year.

In other Bausch Health Companies news, EVP Christina Ackermann sold 19,946 shares of the company’s stock in a transaction dated Tuesday, October 16th. The shares were sold at an average price of $24.98, for a total value of $498,251.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Joseph C. Papa bought 30,000 shares of the firm’s stock in a transaction on Friday, September 14th. The stock was purchased at an average price of $22.32 per share, with a total value of $669,600.00. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 165,000 shares of company stock valued at $3,890,700. 11.54% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. NEXT Financial Group Inc bought a new position in Bausch Health Companies in the 3rd quarter worth about $101,000. Steward Partners Investment Advisory LLC bought a new position in Bausch Health Companies in the 3rd quarter worth about $106,000. Polaris Greystone Financial Group LLC bought a new position in Bausch Health Companies in the 3rd quarter worth about $107,000. Quadrant Capital Group LLC bought a new position in Bausch Health Companies in the 3rd quarter worth about $118,000. Finally, Bedel Financial Consulting Inc. bought a new position in Bausch Health Companies in the 3rd quarter worth about $129,000. Hedge funds and other institutional investors own 42.90% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

See Also: Beta

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply